| Ytd | 26.01% | |
| 1y | -7.10% |
| Open | 7.75 | Prev Close | 7.73 | Low | 7.31 | High | 7.95 | Mkt Cap | 460.67M |
| Vol | 1.25M | Avg Vol | 1.80M | EPS | -1.35 | P/E | N/A | Forward P/E | -1.40 |
| Beta | N/A | Short Ratio | 1.37 | Inst. Own | 66.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 7.11 | 200-d Avg | 6.55 | 1yr Est | 29.14 |
Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel
SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.
https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-as